New drug trial aims to control kidney disease in chinese patients
NCT ID NCT07522099
First seen Apr 14, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the drug is safe and can help control the disease, either alone or with another medication. Participants must have active kidney disease and meet specific health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ADARx Clinical Site
RECRUITINGShenzhen, Guangdong, 518100, China
-
ADARx Clinical Site
RECRUITINGGuiyang, Guizhou, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
ADARx Clinical Site
RECRUITINGBaotou, Inner Mongolia, 014000, China
-
ADARx Clinical Site
RECRUITINGWuxi, Jiangsu, 214000, China
-
ADARx Clinical Site
RECRUITINGYantai, Shandong, 264008, China
-
ADARx Clinical Site
RECRUITINGBeijing, 100034, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGShandong, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGShanghai, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGShangxi, China
Conditions
Explore the condition pages connected to this study.